Second-line erlotinib in unselected NSCLC: audit of benefit

被引：0
|
作者：
Urquhart, G. [1 ]
Semple, E. [2 ]
Steven, E. [1 ]
Kerr, K. [1 ]
Nicolson, M. [1 ]
机构：
[1] Aberdeen Royal Infirm, Aberdeen, Scotland
[2] Univ Aberdeen, Sch Med, Aberdeen AB9 2ZD, Scotland
来源：
LUNG CANCER | 2011年 / 71卷
关键词：
D O I：
10.1016/S0169-5002(11)70011-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [1] Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy
    Fiala, O.
    Pesek, M.
    Finek, J.
    Krejci, J.
    Bortlicek, Z.
    Benesova, L.
    Minarik, M.
    [J]. NEOPLASMA, 2013, 60 (02) : 129 - 134
  • [2] Phase II trial of second-line erlotinib and digoxin for nonsmall cell lung cancer (NSCLC)
    Kayali, Fadi
    Janjua, Muhamad A.
    Laber, Damian A.
    Miller, Donald
    Kloecker, Goetz H.
    [J]. OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2011, 3 : 9 - 13
  • [3] Do NSCLC patients become sensitive to second-line erlotinib treatment after previous radiotherapy?
    Krawczyk, Pawel
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Krzakowski, Maciej
    Milanowski, Janusz
    [J]. KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2010, 7 (04) : 411 - 414
  • [4] Second-Line Therapy for Advanced NSCLC
    Weiss, Jared M.
    Stinchcombe, Thomas E.
    [J]. ONCOLOGIST, 2013, 18 (08): : 947 - 953
  • [5] Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial
    Gridelli, Cesare
    Chella, Antonio
    Valmadre, Giuseppe
    Allegrini, Giacomo
    Brighenti, Matteo
    Bidoli, Paolo
    Rossi, Antonio
    Maione, Paolo
    Migliorino, Maria Rita
    Ricciardi, Serena
    De Marinis, Filippo
    [J]. ANTICANCER RESEARCH, 2016, 36 (12) : 6535 - 6540
  • [6] Nivolumab—an effective second-line treatment for NSCLC
    Diana Romero
    [J]. Nature Reviews Clinical Oncology, 2015, 12 (12) : 685 - 685
  • [7] GEFITINIB, ERLOTINIB AND CHEMOTHERAPY AS SECOND-LINE TREATMENT FOR PATIENT WITH ADVANCED NON-SMALL LUNG CANCER (NSCLC)
    Yang, M.
    Tan, E. C.
    Chen, Y.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A885 - A885
  • [8] Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma
    Wagner, Mathilde
    Besse, Benjamin
    Balleyguier, Corinne
    Soria, Jean-Charles
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : 677 - 679
  • [9] NSCLC second line therapy with erlotinib: review of patients' outcomes
    Urquhart, G.
    Semple, E.
    Steven, E.
    Kerr, K.
    Nicolson, M.
    [J]. LUNG CANCER, 2011, 71 : S6 - S6
  • [10] New perspectives in the second-line treatment of NSCLC with pemetrexed
    Vansteenkiste, J.
    [J]. LUNG CANCER, 2006, 52 : S29 - S30
12345